![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 24-Feb-2012[ | E-mail |
Share ] Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
JUPITER, FL A Scripps Florida team has been awarded nearly $1.5 million by the National Institutes of Health to identify and develop novel potent inhibitors of the human immunodeficiency virus (HIV), the cause of AIDS.
A. Donny Strosberg, a professor on the Florida campus of The Scripps Research Institute, is the principal investigator for the new three-year study.
Current treatments of HIV-infected patients are based on combinations of drugscalled cocktailsthat target several critical key steps in the early and late stages of the viral replication cycle. While these combinations have proven effective in controlling the infection in many patients, the continuous emergence of new multi-resistant viral strains requires the development of new classes of drugs that can be aimed at different targets on HIV.
Strosberg's target is the capsid protein or CA, the primary component of the HIV virionthe infectious particle responsible for transporting the viral genome to host cells. This viral protein forms a cone-shaped shell around the HIV genome, and plays a critical role in the lifecycle of the virus by packaging and organizing the viral genome so that HIV can replicate efficiently.
"Because of the growing resistance of HIV against current treatments, a new, differently targeted approach to treating the disease is urgently needed," Strosberg said. "We expect to use the HIV capsid protein as a new high-throughput screening target for the discovery of novel anti-HIV/AIDS agents."
Identifying new compounds that could target the CA protein might make it possible to prevent the protein's assembly into capsid shells in the first place, blocking the virus's infectivity, and adding a potent complement to existing treatments, he said. This strategy has worked well for Strosberg's group, which has in the past years discovered several potent inhibitors of the hepatitis C virus.
Strosberg and his colleagues, who include Susana Valente, PhD, an assistant professor at Scripps Florida, and Massimo Caputi, PhD, an associate professor of biomedical science at the Florida Atlantic University Charles E. Schmidt College of Medicine, plan to perform an initial screening of some 350,000 compounds in the Molecular Libraries Probe Centers Network at Scripps Research; Scripps Research is one of only four such large probe centers nationwide.
###
About The Scripps Research Institute
The Scripps Research Institute is one of the world's largest independent, non-profit biomedical research organizations. Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neuroscience, and vaccine development, as well as for its insights into autoimmune, cardiovascular, and infectious disease. Headquartered in La Jolla, California, the institute also includes a campus in Jupiter, Florida, where scientists focus on drug discovery and technology development in addition to basic biomedical science. Scripps Research currently employs about 3,000 scientists, staff, postdoctoral fellows, and graduate students on its two campuses. The institute's graduate program, which awards Ph.D. degrees in biology and chemistry, is ranked among the top ten such programs in the nation. For more information, see www.scripps.edu.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 24-Feb-2012[ | E-mail |
Share ] Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
JUPITER, FL A Scripps Florida team has been awarded nearly $1.5 million by the National Institutes of Health to identify and develop novel potent inhibitors of the human immunodeficiency virus (HIV), the cause of AIDS.
A. Donny Strosberg, a professor on the Florida campus of The Scripps Research Institute, is the principal investigator for the new three-year study.
Current treatments of HIV-infected patients are based on combinations of drugscalled cocktailsthat target several critical key steps in the early and late stages of the viral replication cycle. While these combinations have proven effective in controlling the infection in many patients, the continuous emergence of new multi-resistant viral strains requires the development of new classes of drugs that can be aimed at different targets on HIV.
Strosberg's target is the capsid protein or CA, the primary component of the HIV virionthe infectious particle responsible for transporting the viral genome to host cells. This viral protein forms a cone-shaped shell around the HIV genome, and plays a critical role in the lifecycle of the virus by packaging and organizing the viral genome so that HIV can replicate efficiently.
"Because of the growing resistance of HIV against current treatments, a new, differently targeted approach to treating the disease is urgently needed," Strosberg said. "We expect to use the HIV capsid protein as a new high-throughput screening target for the discovery of novel anti-HIV/AIDS agents."
Identifying new compounds that could target the CA protein might make it possible to prevent the protein's assembly into capsid shells in the first place, blocking the virus's infectivity, and adding a potent complement to existing treatments, he said. This strategy has worked well for Strosberg's group, which has in the past years discovered several potent inhibitors of the hepatitis C virus.
Strosberg and his colleagues, who include Susana Valente, PhD, an assistant professor at Scripps Florida, and Massimo Caputi, PhD, an associate professor of biomedical science at the Florida Atlantic University Charles E. Schmidt College of Medicine, plan to perform an initial screening of some 350,000 compounds in the Molecular Libraries Probe Centers Network at Scripps Research; Scripps Research is one of only four such large probe centers nationwide.
###
About The Scripps Research Institute
The Scripps Research Institute is one of the world's largest independent, non-profit biomedical research organizations. Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neuroscience, and vaccine development, as well as for its insights into autoimmune, cardiovascular, and infectious disease. Headquartered in La Jolla, California, the institute also includes a campus in Jupiter, Florida, where scientists focus on drug discovery and technology development in addition to basic biomedical science. Scripps Research currently employs about 3,000 scientists, staff, postdoctoral fellows, and graduate students on its two campuses. The institute's graduate program, which awards Ph.D. degrees in biology and chemistry, is ranked among the top ten such programs in the nation. For more information, see www.scripps.edu.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2012-02/sri-sft022412.php
occupy dc ufc 143 fight card my fair lady conversion disorder the chronicle spinal stenosis the forgotten man
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.